Neola Medical AB (publ) has been granted a patent in the U.S. for a technical solution that reduces noise in measurements for continuous lung monitoring. The patent protects an innovation designed to reduce interference in an optical fiber, supporting more stable and consistent measurement data throughout monitoring. Patent is approved in China and an application is pending in Europe.
“This U.S. patent further strengthens Neola Medical’s intellectual property position in a key market and adds protection within a new patent family. By addressing optical interference in the measurement process, the invention supports the continued refinement of Neola® and our ambition to deliver reliable continuous lung monitoring for the most vulnerable patients,” says CEO Hanna Sjöström.
About the patent
The granted patent belongs to Neola Medical’s patent family “A device for smoothing spectral transmission modulations and a method thereof” and protects the company’s innovation for optimizing measurement data by reducing interference in the optical fiber during lung monitoring.